Tuberculosis

被引：5
作者：
Kelly, Ana M. [1 ]
机构：
[1] Columbia Univ, Sch Nursing, 560 West 168th St, New York, NY 10027 USA
来源：
NURSING CLINICS OF NORTH AMERICA | 2019年 / 54卷 / 02期
关键词：
Tuberculosis; Latent TB; Screening; MYCOBACTERIUM-TUBERCULOSIS; DISEASES SOCIETY; INFECTION; TRANSMISSION; RIFAPENTINE; GUIDELINES; PREVENTION; DIAGNOSIS; ADULTS;
D O I：
10.1016/j.cnur.2019.02.008
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
Drug-resistant tuberculosis (TB) is one of the greatest challenges facing the elimination of TB. In the United States, persons born outside the United States account for 70% of new TB cases. Nucleic acid amplification testing has greatly reduced the amount of time needed for diagnosis of TB, down to 1 to 2 days, compared with waiting 21 days for culture results. The shorter treatment regimen for latent TB infection with weekly isoniazid and rifabutin for 12 weeks provides treatment as effective as the traditional daily isoniazid for 6 months, but with better adherence from patients.
引用
收藏
页码：193 / +
页数：14
相关论文
共 31 条
  • [1] [Anonymous], 2016, DRUG RES TUB SURV GU
  • [2] Belknap R, 2017, ANN INTERN MED, V167, P689, DOI [10.7326/M17-1150, 10.7326/m17-1150]
  • [3] Benator D, 2002, LANCET, V360, P528, DOI 10.1016/S0140-6736(02)09742-8
  • [4] The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach
    Borgdorff, Martien W.
    Sebek, Maruschka
    Geskus, Ronald B.
    Kremer, Kristin
    Kalisvaart, Nico
    van Soolingen, Dick
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2011, 40 (04) : 964 - 970
  • [5] Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection
    Borisov, Andrey S.
    Morris, Sapna Bamrah
    Njie, Gibril J.
    Winston, Carla A.
    Burton, Deron
    Goldberg, Stefan
    Woodruff, Rachel Yelk
    Allen, Leeanna
    LoBue, Philip
    Vernon, Andrew
    [J]. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2018, 67 (25): : 723 - 726
  • [6] Centers for Disease Control and Prevention, DIAGN LAT TB INF TB
  • [7] Centers for Disease Control and Prevention, NAT TB PROGR OBJ PER
  • [8] Centers for Disease Control and Prevention, TREATM LAT TUB INF L
  • [9] Centers for Disease Control and Prevention National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention Division of Tuberculosis Elimination, 2017, REP TUB US
  • [10] EFFICACY OF BCG VACCINE IN THE PREVENTION OF TUBERCULOSIS - METAANALYSIS OF THE PUBLISHED LITERATURE
    COLDITZ, GA
    BREWER, TF
    BERKEY, CS
    WILSON, ME
    BURDICK, E
    FINEBERG, HV
    MOSTELLER, F
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (09): : 698 - 702
1234